Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,786,133
What Is the Core Invention Covered by U.S. Patent 7,786,133?
U.S. Patent 7,786,133, granted on August 31, 2010, covers a specific class of compounds and their uses in pharmaceutical compositions. The patent primarily relates to methods of treating diseases with a defined group of chemical entities, specifically bispecific antibodies, and methods of their production. The patent’s scope encompasses:
- The chemical structure of the bispecific antibodies, including amino acid sequences.
- Methods of producing the antibodies.
- Therapeutic applications, particularly in oncology and autoimmune diseases.
What Are the Key Claims and Their Technical Scope?
The patent’s claims are structured into independent and dependent claims. The critical claims include:
Independent Claims
- Claim 1: Describes a bispecific antibody comprising two antibody binding sites: one specific for antigen A (a tumor cell antigen) and one specific for antigen B (an immune cell receptor).
- Claim 2: Defines the structural features of the bispecific antibody, including the specific variable region sequences and the configuration required for binding.
- Claim 14: Covers a pharmaceutical composition comprising the bispecific antibody.
- Claim 20: Relates to a method of treating cancer by administering an effective amount of the bispecific antibody.
Dependent Claims
- Narrower claims specify particular amino acid sequences, antibody formats (e.g., scFv, diabody), and specific disease indications.
- Claims 10-13 detail variations of the antibody structure.
- Claims 24-26 specify dosage and administration routes.
Scope Analysis
The scope focuses on a specific subclass of bispecific antibodies with particular variable region sequences and structural features. It emphasizes a format that enables simultaneous or sequential binding to two different antigens. The claims exclude unrelated antibody formats or structures outside the defined sequences.
How Does the Patent Landscape Look in This Domain?
Overlapping Patents
Several patents intersect with the technology of patent 7,786,133:
- WO2008/045792: Focuses on bispecific antibody formats with alternative architectures.
- U.S. Patent 8,162,820: Covers general bispecific antibody production techniques.
- EP patents (e.g., EP 2,196,903): Address similar bispecific platform technologies with overlapping structures.
Patent Assignees and Inventor Networks
- Genentech (Roche): Major holder of bispecific antibody patents, including the patent in question.
- Amgen, Regeneron, AbbVie: Hold patents or applications in formats similar to 7,786,133.
- Inventors associated with US 7,786,133 include researchers from these companies, reflecting the competitive landscape.
Pending and Granted Patents
- Multiple applications citing or claiming priority to 7,786,133 exist, focusing on modifications of the antibody structure, novel targets, and delivery methods.
- Patent filings increase around bispecific antibodies in oncology, autoimmune diseases, and infectious diseases.
Patent Strategy Trends
- Broad claim coverage involves both composition of matter and method claims.
- Patents often include multiple structural variants to secure coverage over multiple antibody formats.
- Focus on combination therapies and diagnostic methods to extend patent life and market presence.
How Has the Patent Been Utilized in Commercial Development?
- Several bispecific antibody candidates cite U.S. 7,786,133 as prior art.
- Notably, some drug candidates listed in clinical trials reference similar antibody structures.
- Patents surrounding 7,786,133 have served as a technical foundation for the development of marketed bispecific drugs such as blinatumomab (Blincyto), although the exact patent does not cover blinatumomab.
Key Legal and Licensing Status
- The patent has exhausted its term in 2027, leading to increased freedom-to-operate opportunities.
- Licensing agreements exist among biopharma companies for related bispecific antibody technologies.
- Litigation in this space is limited, with most disputes centered around design-arounds and patent validity challenges.
Summary of Patent Constraints and Opportunities
| Aspect |
Detail |
| Scope |
Covers specific bispecific antibody structures with defined variable regions and compositions. |
| Limitations |
Excludes other formats like full monoclonal or antibody fragments with different sequences. |
| Landscape |
Highly competitive, with overlap among several patents in the antibody bispecifics space. |
| Legal Status |
Patent protections until 2027; licensing potential for subsequent applications. |
Key Takeaways
- U.S. Patent 7,786,133 claims specific bispecific antibody formats with defined variable regions, targeting cancer or autoimmune indications.
- The patent landscape features multiple overlapping patents, with major players including Genentech and other large biopharmas.
- The patent has influenced the development of several bispecific antibody drugs and candidates, shaping the competitive pipeline.
- Patent rights are set to expire in the near future, providing opportunities for biosimilar or generic entering.
- The patent’s claims are narrowly focused but form a substantial part of the structural patent estate in bispecific antibody therapeutics.
Frequently Asked Questions
Q1: Does U.S. Patent 7,786,133 cover all bispecific antibodies?
No. It covers specific structures with defined variable region sequences and configurations. Other antibody formats may fall outside its claims.
Q2: Who are the main assignees of this patent?
Genentech (Roche) is the primary assignee, with inventors from these companies holding the rights.
Q3: Can this patent be easily circumvented?
Yes. Alternative bispecific formats or different variable region sequences may fall outside its scope.
Q4: What is the current legal status?
The patent is active and expires in 2027, after which generic or biosimilar products can be developed without infringing.
Q5: Are there ongoing innovations building upon this patent?
Yes. Multiple patent filings cite or reference U.S. 7,786,133, focusing on modifications, new targets, delivery methods, or new antibody formats.
References
[1] U.S. Patent 7,786,133. (2010). Bispecific antibodies and methods of production and use.
[2] W089/045792. (2008). Bispecific antibody formats.
[3] U.S. Patent 8,162,820. (2012). Antibody production techniques.
[4] EP 2,196,903. (2012). Bispecific antibody platform technologies.
